Defense technology is shifting from a venture-funded innovation asset class into a heavy-asset sector that needs industrial-scale production. The meaningful change is not the volume of money but its character: venture capital can wait, while a private equity fund has a clock.
It is the first time a German luxury marque has established whole-vehicle production capacity on American soil. For a company that enters the market mainly through finished-vehicle exports, local production moves tariff cost from the income statement into capital expenditure.
Extending restrictions from computing power into pharmaceutical research capability means the target of US-China friction is shifting from physical equipment toward irreplaceable knowledge assets. The carve-out reveals how US policymakers balance economic pressure against pharmaceutical revenue in China.